| Item 1.01. | Entry into a Material Definitive Agreement. |
On September 28, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the “Underwriters”), for the sale of (i) 1,248,098 shares of common stock (the “Shares”) of the Company, $0.0001 par value per share (the “Common Stock”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,048,098 shares of Common Stock in an underwritten public offering (the “Offering”). The public offering price for the Shares is $151.69 per share, less underwriting discounts and commissions. The public offering price for the Pre-Funded Warrants is $151.6899 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The exercise price of the Pre-Funded Warrants is $0.0001. Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to 494,429 additional shares of Common Stock, at the public offering price, less the underwriting discount and commissions.
The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to the Company.
The Company estimates net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses payable by the Company, will be approximately $472.0 million, excluding any exercise of the Underwriter’s option to purchase additional shares. The closing of the Offering is expected to occur on October 3, 2023, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from this offering for its clinical and commercial activities in preparation for a potential launch of resmetirom in the U.S. and general corporate purposes, including, without limitation, research and development expenditures, clinical trial expenditures, manufacture and supply of drug substance and drug products, potential acquisitions or licensing of new technologies, capital expenditures and working capital.
The Company made certain representations, warranties and covenants in the Underwriting Agreement and also agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.
In connection with the Underwriting Agreement, the Company and the Company’s directors and executive officers also agreed not to sell or transfer any Common Stock without first obtaining the written consent of the Underwriter, subject to certain exceptions, for 60 days after the date of the Prospectus (as defined in the Underwriting Agreement).
A copy of the Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and incorporated herein by reference. The foregoing is only a brief description of the material terms of the Underwriting Agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to Exhibit 1.1. The form of Pre-Funded Warrant is filed to this Current Report on Form 8-K as Exhibit 4.1, and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit. The legal opinion of Hogan Lovells US LLP related to the offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.
